Psychedelic Science Newsletter
Issue #32April 13, 20267 studies

Psilocybin activates the same brain networks across 5 different psychedelics

This week brought a treasure trove of psychedelic research—from the largest brain imaging study ever conducted on these compounds to new insights about training therapists and managing risks. Here's what scientists discovered.

🧠 Mega brain study reveals psychedelics' shared neural signature

  • Scientists combined brain scans from 11 independent studies across 5 psychedelics (psilocybin, LSD, mescaline, DMT, and ayahuasca) to create the most comprehensive map of how these drugs alter brain function

  • The analysis revealed a consistent pattern: all psychedelics increased connections between high-level brain networks (like the default mode network) and sensory regions (visual and motor areas)

  • Key subcortical regions including the thalamus, caudate, and putamen showed altered coupling with sensorimotor networks across all compounds

Why it matters: This mega-analysis helps resolve inconsistencies from smaller studies and provides the clearest picture yet of psychedelics' shared mechanisms in the brain—crucial for understanding how they might work therapeutically.

🔗 Nature medicine Journal Article 🗓️ Apr 6

Key Findings

🎯 Psychedelic therapy works better with regular therapists involved

  • A comprehensive review found no cohesive framework exists for coordinating care between external therapists and specialized psychedelic treatment teams

  • External therapists play critical roles across all phases—preparation, dosing, and integration—contributing to patient safety and continuity of care

  • The analysis suggests psychedelic-assisted therapy should not be viewed as a standalone treatment for patients with treatment-resistant conditions

💡 This challenges the narrative of psychedelics as discrete interventions and points toward more integrated therapeutic approaches.
Top 20% journal 🔗 Brain and behavior Review 🗓️ Apr 10

⚡ Ketamine mystical experiences predict better depression outcomes

  • Among 45 patients receiving esketamine treatment, 58% experienced mystical-type effects (scoring ≥60 on a validated mystical experience scale)

  • Higher mystical experience scores were associated with greater improvement in depression ratings, while dissociative effects showed no such link

  • Patients with higher baseline spirituality had better treatment outcomes and more intense mystical experiences in the first week

💡 This suggests the subjective quality of ketamine experiences, not just the drug itself, may influence therapeutic benefits.

🔬 MDMA training shows modest improvements for nurse facilitators

  • Nine nurses completed a 15-week training program for MDMA-assisted therapy, with objective assessment using standardized role-plays

  • Training showed significant improvement in only 1 of 12 measured relational skills, with medium to large effect sizes for 6 measures

  • Most facilitators reported needing additional hands-on training to feel adequately prepared for delivering the treatment

💡 This highlights the challenge of training non-psychologist facilitators and suggests different professionals may need tailored preparation programs.
Top 20% journal 🔗 BMC medical education Journal Article 🗓️ Apr 9

🧬 Psilocybin triggers stress-response genes across brain regions

  • In rats, psilocybin (2 mg/kg) upregulated specific genes in 5 brain regions rich in serotonin 5-HT2A receptors 90 minutes after administration

  • Two genes (Nfkbia and Sgk1) were upregulated in all studied regions, while Ddit4 was upregulated in four regions

  • Many of the affected genes are known to be activated by stress hormones like cortisol, suggesting psilocybin may work through stress-response pathways

💡 This points to a potential connection between psychedelics' therapeutic effects and the body's stress response systems.
Top 20% journal 🔗 Acta neuropsychiatrica Journal Article 🗓️ Apr 10

💊 Ibogaine derivative reduces alcohol drinking in rats

  • Oxa-noribogaine, a modified version of ibogaine, reduced alcohol consumption in rat models of alcohol dependence without detectable motor or cardiac side effects

  • The compound worked by strengthening learning from negative drinking outcomes and produced lasting changes in brain glutamate signaling

  • Effects were sustained and matched or exceeded the parent compound ibogaine's efficacy across multiple translational models

💡 This suggests a potentially safer alternative to ibogaine for treating alcohol use disorder may be on the horizon.
🔗 Research square Preprint 🗓️ Apr 10

⚠️ Regular psychedelic users show altered emotional brain responses

  • Brain scans of 33 experienced psychedelic users (≥10 lifetime uses) compared to 34 matched controls revealed faster, more accurate recognition of angry facial expressions

  • Users showed reduced activation in limbic and salience brain regions when viewing angry faces, plus heightened responses to happy expressions in sensory areas

  • Two default mode network regions showed less differentiation between different emotional categories in experienced users

💡 This suggests regular psychedelic use may durably alter how the brain processes emotional information, though the clinical significance remains unclear.
🎖️ Top 10% journal 🔗 Human brain mapping Journal Article 🗓️ Apr 9

Implications

This week's research paints a picture of psychedelics as complex interventions that require careful integration with traditional therapy and specialized training. The convergent brain imaging findings provide a foundation for understanding these drugs' mechanisms, while studies on training, safety, and long-term effects highlight the practical challenges of bringing psychedelic medicine into mainstream healthcare.

Studies in this issue

Primary sources used for this newsletter.

  1. Psychedelic drugs’ effects on brain circuits: an international combined analysis
    main storyNature medicine2026-04-06PMID 41942645
  2. Important Points About Using Psychedelics Alongside Therapy
    key findingBrain and behavior2026-04-10PMID 41958148
  3. Psilocybin triggers a stress-related gene response in five serotonin receptor–rich brain areas in rats
    key findingActa neuropsychiatrica2026-04-10PMID 41958297
  4. Emotional Responses in Experienced Psychedelic Users Measured by Brain Imaging
    key findingHuman brain mapping2026-04-09PMID 41954041
  5. Training program for guides in a controlled trial of psilocybin treatment for depression
    key findingBMC medical education2026-04-09PMID 41952163
  6. Mystical Experiences Linked to Esketamine Treatment in Real-World Use
    key findingmedRxiv : the preprint server for health sciences2026-04-10PMID 41959772
  7. Oxa-noribogaine reduces alcohol drinking by causing unpleasant memories and changing nerve signals in the decision-making brain area
    key findingResearch square2026-04-10PMID 41960323

Continue reading

All Psychedelic Science issues